



1. A process for inhibiting NF- $\kappa$ B in a mammalian cell in which NF- $\kappa$ B has been activated by an agency external to said cell which comprises administering to the mammal in whose cells NF- $\kappa$ B has been activated an NF- $\kappa$ B inhibiting amount of a drug represented by the formula:



wherein n is 2-5, m is 0 or 1, R is NH<sub>2</sub>, NHOH, OC<sub>1</sub>-alkyl, or O-phenyl, R' is O, NH or NOH, R" is H or OH, or a pharmaceutically- acceptable acid addition salt or acylated phenol derivative thereof.



533  
514/534  
575  
617

ABIK 31/235  
31/195  
31/165

BEST AVAILABLE COPY

ADDENDUM

CLAIMS ON APPEAL

- 2) A process according to Claim ~~14~~<sup>1</sup> in which the external agency activating NF- $\kappa$ B in an inflammatory process includes, but is not limited to, a cytokine, an activator of protein kinase B, a virus or an oxidant.
- 3) A process according to Claim ~~14~~<sup>1</sup> in which the external agency activating NF- $\kappa$ B is a drug or radiation administered to the host mammal in a chemotherapeutic process used in the treatment of cancer.
- 4) A process according to Claim ~~14~~<sup>1</sup> in which the administered NF- $\kappa$ B inhibitor is a free-radical scavenger.
- 5) A therapeutic process according to Claim ~~14~~<sup>1</sup> in which the NF- $\kappa$ B inhibitor is N,3,4-trihydroxybenzamide.
- 6) A therapeutic process according to Claim ~~14~~<sup>1</sup> in which the NF- $\kappa$ B inhibitor is N,3,4,5-tetrahydroxybenzamide.
- 7) A therapeutic process according to Claim ~~14~~<sup>1</sup> in which the NF- $\kappa$ B inhibitor is N, 3,4-tetrahydroxybenzimidamide. 8) A therapeutic process according to Claim ~~14~~<sup>1</sup> in which the NF- $\kappa$ B inhibitor is a ribonucleotide reductase inhibitor.
- 9) A process according to Claim ~~14~~<sup>1</sup> in which the external agency activating NF- $\kappa$ B is the result of a tissue transplant, an organ transplant or a cell transplant in a mammal.
- 10) A process according to Claim ~~14~~<sup>1</sup> in which the external agency activating NF- $\kappa$ B is arteriosclerosis.
- 11) A process according to Claim ~~14~~<sup>1</sup> in which the external agency activating NF- $\kappa$ B is diabetes.

BEST AVAILABLE COPY